Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NasalCEASE

This article was originally published in The Tan Sheet

Executive Summary

The first FDA-approved nonprescription treatment for minor nosebleeds has hit the shelves of more than 5,400 CVS stores, according to an announcement by Mendon, N.Y.-based marketer Catalina Healthcare Feb. 1. NasalCEASE is a small sterile nasal packing made of a highly absorbent "natural 'bio-polymer' extracted from brown seaweed." It releases calcium to stop bleeding and "turns moist to prevent sticking to clots." FDA approval of the 510(k) device application was received in July 2004, but the product initially was only available through doctors and some independent pharmacies. Catalina Healthcare is a subsidiary of the French firm Les Laboratoires Brothier, and the product has been available over-the-counter in Europe for several years. A box of five individually wrapped sterile packs carries an SRP of $11.50. The firm plans to build consumer awareness through a national radio campaign slated to begin in April...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel